Immuron always sells off after financial reporting. Be it...

Immuron always sells off after financial reporting. Be it 6monthly or annual report. Nothing has changed. Those buyers who have been happily buying in the last week are here because of our pipeline, ongoing sales growth, collaborations , fully funded for the Travelan testing trials with US Army & US Navy, collaborations & fully funded by USA NIH for ASH & Pedriatric NASH. We're funding Cdiff trial & phase 2 NASH trial. NASH ph2 final redults any day , market cap is less than $40mio in Aud$ or ~USD$30mio. Good results can send the sp 10x+ higher. Then a bigpharma deal & large upfront of USD$100mio cash (no dilution) or sell whole Immuron company & pipeline for a paltry $1billion USD! So you see the sellers are very silly, afraid, risk averse individuals & want to chase buying back in much, much higher sp after good results, worldwide media reports etc, etc. I'm staying long of my shares, options & warrants for the amazing rewards which will be well deserved.